Trial · NCT01009086
Adverse events490
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 490
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Placebo (CP) | 8 | 205 | |
| other | Nasopharyngitis | Infections and infestations | Ustekinumab 45 mg (CP) | 8 | 205 | |
| other | Nasopharyngitis | Infections and infestations | Ustekinumab 90 mg (CP) | 11 | 204 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (After CP) | 2 | 140 | |
| other | Nasopharyngitis | Infections and infestations | Placebo -> Ustekinumab 45 mg (After CP) | 15 | 189 | |
| other | Nasopharyngitis | Infections and infestations | Ustekinumab 45 mg (After CP) | 18 | 203 | |
| other | Nasopharyngitis | Infections and infestations | Ustekinumab 90 mg (After CP) | 20 | 199 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo (CP) | 10 | 205 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ustekinumab 45 mg (CP) | 5 | 205 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ustekinumab 90 mg (CP) | 9 | 204 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo (After CP) | 2 | 140 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo -> Ustekinumab 45 mg (After CP) | 16 | 189 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ustekinumab 45 mg (After CP) | 14 | 203 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ustekinumab 90 mg (After CP) | 12 | 199 | |
| other | Urinary Tract Infection | Infections and infestations | Placebo (CP) | 2 | 205 | |
| other | Urinary Tract Infection | Infections and infestations | Ustekinumab 45 mg (CP) | 1 | 205 | |
| other | Urinary Tract Infection | Infections and infestations | Ustekinumab 90 mg (CP) | 2 | 204 | |
| other | Urinary Tract Infection | Infections and infestations | Placebo (After CP) | 1 | 140 | |
| other | Urinary Tract Infection | Infections and infestations | Placebo -> Ustekinumab 45 mg (After CP) | 6 | 189 | |
| other | Urinary Tract Infection | Infections and infestations | Ustekinumab 45 mg (After CP) | 4 | 203 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01009086/events